114 related articles for article (PubMed ID: 33780038)
1. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Short NJ; Konopleva M; Kadia T; Kebriaei P; Daver N; Huang X; Masarova L; Cook R; Jain N; Jabbour E; Kantarjian H; Ravandi F
Am J Hematol; 2021 Jul; 96(7):E229-E232. PubMed ID: 33780038
[No Abstract] [Full Text] [Related]
2. A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study.
Tang H; Jia W; Jia S; Dong R; Gao S; Feng J; Dong H; Gu H; Zhang T; Yuan R; Liu X; Cheng L; Zhou S; Gao G
Am J Hematol; 2024 Jun; 99(6):1177-1179. PubMed ID: 38482543
[No Abstract] [Full Text] [Related]
3. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Eyre TA; Walter HS; Iyengar S; Follows G; Cross M; Fox CP; Hodson A; Coats J; Narat S; Morley N; Dyer MJS; Collins GP
Haematologica; 2019 Feb; 104(2):e68-e71. PubMed ID: 30190341
[No Abstract] [Full Text] [Related]
4. Pairing obinutuzumab with venetoclax in relapsed CLL.
Rogers KA; Thompson PA
Leuk Lymphoma; 2024 May; 65(5):543-545. PubMed ID: 38497550
[No Abstract] [Full Text] [Related]
5. Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
Hao Z; Fei Y; Chen J; Huang S; Wang L; Yu Y; Bian M; Si Y; Zhang X; Yang X; Zhang B; Wan Y; Zhang Y; Lin G
Hematology; 2024 Dec; 29(1):2344998. PubMed ID: 38666535
[TBL] [Abstract][Full Text] [Related]
6. Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.
Khan WJ; Ali M; Hashim S; Nawaz H; Hashim SN; Safi D; Inayat A
J Oncol Pharm Pract; 2024 Apr; 30(3):552-561. PubMed ID: 38113108
[TBL] [Abstract][Full Text] [Related]
7. Fatal tumor lysis syndrome in a pediatric patient with acute lymphoblastic leukemia treated with venetoclax.
Trinder SM; Soggee J; Spragg J; Alexander D; Mitchell R; Gottardo NG; Ramachandran S
Pediatr Blood Cancer; 2024 Mar; 71(3):e30841. PubMed ID: 38149837
[No Abstract] [Full Text] [Related]
8. Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma.
Dima D; Orland M; Ullah F; Anwer F; Mazzoni S; Raza S; Chaulagain CP; Samaras C; Valent J; Williams L; Khouri J
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):857-860. PubMed ID: 37558531
[No Abstract] [Full Text] [Related]
9. Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
Pocock R; Farah N; Richardson SE; Mansour MR
Br J Haematol; 2021 Jul; 194(1):28-43. PubMed ID: 33942287
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
Short NJ; Jabbour E; Nasr LF; Jain N; Haddad FG; Issa GC; Sasaki K; Senapati J; Kebriaei P; Garris R; Konopleva M; Ravandi F; Kantarjian H
Am J Hematol; 2024 Apr; ():. PubMed ID: 38607091
[No Abstract] [Full Text] [Related]
11. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
Sasaki K; Kantarjian HM; Short NJ; Samra B; Khoury JD; Kanagal Shamanna R; Konopleva M; Jain N; DiNardo CD; Khouri R; Garcia-Manero G; Kadia TM; Wierda WG; Khouri IF; Kebriaei P; Mehta RS; Champlin RE; Garris R; Cheung CM; Daver N; Thompson PA; Yilmaz M; Ravandi F; Jabbour E
Cancer; 2021 Aug; 127(15):2648-2656. PubMed ID: 33793964
[TBL] [Abstract][Full Text] [Related]
12. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
Rausch CR; DiNardo CD; Maiti A; Jammal NJ; Kadia TM; Marx KR; Borthakur G; Savoy JM; Pemmaraju N; DiPippo AJ; Daver NG; Chew SM; Sasaki K; Issa GC; Short NJ; Takahashi K; Ohanian MN; Ning J; Xiao L; Alvarado Y; Kontoyiannis DP; Ravandi F; Kantarjian HM; Konopleva MY
Cancer; 2021 Jul; 127(14):2489-2499. PubMed ID: 33793970
[TBL] [Abstract][Full Text] [Related]
13. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.
Wieduwilt MJ; Stock W; Advani A; Luger S; Larson RA; Tallman M; Appelbaum F; Zhang MJ; Bo-Subait K; Wang HL; Bhatt VR; Dholaria B; Eapen M; Hamadani M; Jamy O; Prestidge T; Pulsipher M; Ritchie D; Rizzieri D; Sharma A; Barba P; Sandmaier BM; de Lima M; Kebriaei P; Litzow M; Saber W; Weisdorf D
Leukemia; 2021 Jul; 35(7):2076-2085. PubMed ID: 33785862
[TBL] [Abstract][Full Text] [Related]
14. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia.
Oshima K; Zhao J; Pérez-Durán P; Brown JA; Patiño-Galindo JA; Chu T; Quinn A; Gunning T; Belver L; Ambesi-Impiombato A; Tosello V; Wang Z; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Balbin M; Nicolas C; Gastier-Foster JM; Devidas M; Loh ML; Paietta E; Tallman MS; Rowe JM; Litzow M; Minden MD; Meijerink J; Rabadan R; Ferrando A
Nat Cancer; 2020 Nov; 1(11):1113-1127. PubMed ID: 33796864
[TBL] [Abstract][Full Text] [Related]
15. Oral Azacitidine Maintenance for Acute Myeloid Leukemia.
Perissinotti AJ; Benitez LL; Marini BL
N Engl J Med; 2021 Apr; 384(13):e51. PubMed ID: 33789022
[No Abstract] [Full Text] [Related]
16. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.
Maiti A; DiNardo CD; Wang SA; Jorgensen J; Kadia TM; Daver NG; Short NJ; Yilmaz M; Pemmaraju N; Borthakur G; Bose P; Issa GC; Ferrajoli A; Jabbour EJ; Jain N; Garcia-Manero G; Ohanian M; Takahashi K; Montalban-Bravo G; Masarova L; Burger JA; Thompson PA; Verstovsek S; Sasaki K; Andreeff M; Rausch CR; Montalbano KS; Pierce S; Qiao W; Ning J; Kantarjian HM; Konopleva MY; Ravandi F
Blood Adv; 2021 Apr; 5(7):1876-1883. PubMed ID: 33792630
[TBL] [Abstract][Full Text] [Related]
17. Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase.
Castagnetti F; Pane F; Rosti G; Saglio G; Breccia M
Front Oncol; 2021; 11():642005. PubMed ID: 33796468
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukaemia in patients we judge as being older and/or unfit.
Lazarevic VL
J Intern Med; 2021 Aug; 290(2):279-293. PubMed ID: 33780573
[TBL] [Abstract][Full Text] [Related]
19. Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia.
Niu X; Rothe K; Chen M; Grasedieck S; Li R; Nam SE; Zhang X; Novakovskiy GE; Ahn YH; Maksakova I; Lai S; Zhang H; Yan J; Liu H; Zhao Y; Wu D; Ge Y; Wasserman WW; Rouhi A; Kuchenbauer F; Yip CK; Zhang Z; Jiang X
Blood; 2021 Jul; 137(26):3641-3655. PubMed ID: 33786587
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
